Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Executes $350K Promissory Note

NEW YORK (GenomeWeb) – CombiMatrix said recently in its Form 10-Q that it executed a secured promissory note for $350,000 bearing a 10 percent annual interest rate.

In its document filed with the US Securities and Exchange Commission, the company said that it executed the promissory note on May 20 with ACC Investment. The note is secured by certain laboratory equipment used in its microarray services business and will be payable over a 36-month period. As of June 30 the fair value of the note was about $312,000.

CombiMatrix recently reported that its second quarter revenues were up 29 percent year over year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.